Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)
Condition(s):Multiple SclerosisLast Updated:August 16, 2023Completed
Hide Studies Not Open or Pending
Condition(s):Multiple SclerosisLast Updated:August 16, 2023Completed
Condition(s):Relapsing Remitting Multiple SclerosisLast Updated:April 21, 2023Active, not recruiting
Condition(s):Cerebrovascular DisordersLast Updated:September 22, 2022Recruiting
Condition(s):Tumor, Brain; Cavernoma; Arteriovenous Malformations; Intracerebral HematomaLast Updated:November 30, 2022Recruiting
Condition(s):DementiaLast Updated:June 18, 2023Recruiting
Condition(s):Demyelinating Diseases; Demyelination; Corpus Callosum; Multiple Sclerosis Brain Lesion; Multiple Sclerosis Acute and Progressive; Clinically Isolated Syndrome, CNS DemyelinatingLast Updated:February 20, 2024Not yet recruiting
Condition(s):Focal Brain Injury; CognitionLast Updated:January 17, 2024Recruiting
Condition(s):Recurrent Glioblastoma Multiforme (GBM); Grade 3 Isocitrate Dehydrogenase (IDH) Wildtype Astrocytoma; Grade 3 or 4 Astrocytoma; Glioblastoma SurgeryLast Updated:November 17, 2022Terminated
Condition(s):Spastic Cerebral Palsy; Acquired Brain InjuryLast Updated:July 21, 2023Recruiting
Condition(s):GliomaLast Updated:September 15, 2009Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.